Considerable attention has been directed towards attempting to replace or repair mitral valves using transvascular techniques. More than 40 such novel mitral valve therapeutic devices (MVTDs) that are intended to be delivered using transvascular interventional techniques have been described at this time. Many MVTDs are delivery devices for use in delivering a mitral valve prosthesis. In order for these devices to be considered minimally invasive, interventional cardiology based procedures, they must cross from the right side of the heart to the left side across the inter-atrial septum in a well-established technique known as transseptal catheterization. Because of the size and odd shape of the mitral valve carried by the replacement MVTDs, this route has proven to be extremely difficult.
All current transseptal mitral valve delivery systems rely on the traditional interventional approach that requires that these large devices be pushed over a 0.035 in. guidewire that has been previously introduced across the interatrial septum, through the left atrium then across the mitral valve and into the left ventricle. This guidewire, used in all currently available transseptal interventional devices, provides a “rail” over which these large devices can potentially be forced into position. Unfortunately, the MVTDs generally are simply too big and too rigid to negotiate the tight bends that are required when crossing into and navigating through the left atrium. As a result, they can become “stuck” when attempting to negotiate the multiple turns required for positioning within the mitral valve ring. In some instances, physicians have attempted to force these devices over the guidewire, while using the wire and the device itself to deflect off of delicate cardiac tissues, in order to achieve proper positioning within the mitral valve ring. This use of force is best avoided to prevent damage to the cardiac tissue.
In the embodiments described in this application, guidewires are not utilized to drive movement of the MVTDs into their target position for treatment (e.g. repair or replacement) of the mitral valve. Instead, protected, coordinated and synergistic forces are used to safely position the MVTDs into place. These forces include a pulling force, a pushing force, and a steering force helping to safely advance the MVTD through the vasculature into position and properly orient it relative to the mitral valve.
Attempts have been made to facilitate guidewire delivery of MVTS's by using commercially available “snare devices” delivered retrograde from the aorta through the left ventricle and left atrium in an unprotected fashion to help direct the tips of the delivery systems. These efforts were abandoned when it was found that pulling on the MVTD with a snare resulted in pulling the snare with great force up (superiorly) and across both the aortic and mitral valve leaflets leading to simultaneous wide open insufficiency of both valves and loss of blood pressure in the patient. The disclosed system eliminates this problem, allowing maximum application of force to deliver any mitral therapeutic device safely into precise position within the mitral valve ring.
The presently disclosed system is designed to aid in the delivery of a MVTD to a mitral valve location. The terms “mitral valve therapeutic device” or “MVTD” used here refer to any device that may be delivered to the native mitral valve site for a therapeutic purpose. In the description that follows, the MVTD is shown as a mitral valve delivery system carrying a replacement mitral valve, but it should be understood that the system and method described may be used to deliver other types of MVTD's such as those used to repair a mitral valve.
The disclosed system and method replaces the traditional interventional guidewire approach used for MVTD delivery with a percutaneous system that allows the MVTD to be safely towed to the mitral valve site within the heart. Although the system can easily be attached to any existing MVTD via the intrinsic 0.035 in. lumen present in all such interventional devices, it eliminates the need for a guidewire with the MVTD.
As will be appreciated from a review of the more detailed discussion that follows, the cable system functions to both push the proximal end of the MVTD while simultaneously pulling on the distal nose of it with equal and coordinated force to drive the MVTD across the interatrial septum. Pulling down further on the distal nose of the MVTD using the cable provides a steering force that serves to direct the stiff, bulky MVTD into position across the interatrial septum, into the left atrium and into position for deployment in the mitral valve ring (located below the interatrial septal entry point and to the patient's left). The MVTD is further positioned precisely in the center at an angle that is perpendicular to the MV plane by use of a steering mechanism present in a unique device referred to as the LV redirector (described in detail below). In some embodiments, an electronic drive unit may be used to deliver precisely coordinated pushing and pulling forces.
In the description of system and method below, the access points for the components of the system are described as the right femoral vein for the venous access and the left femoral artery for the arterial access. However, the system and method can just as readily be used with a different combination of venous and arterial access. For example, venous access may be gained via the right femoral vein and arterial access may be gained via the right femoral artery. Alternatively, both access points may be on the left side. In yet another embodiment, venous access is gained via the left femoral vein and arterial access is gained via the right femoral artery.
System
Referring to
The system further includes a tracker balloon catheter 16, shown extending through the RLC 10 in
In
A membrane 30 is positioned along a portion of the distal part of the shaft and along the external portion of the pullwire 36. When the pullwire is relaxed and the shaft is in the straight configuration, the panel and pull wire run along the distal part of the shaft. The membrane forms the D-shaped barrier shown in
Note that the term “pullwire” is not intended to mean that the pullwires must be formed of wire, as that term is used more broadly in this application to represent any sort of tendon, cable, or other elongate element the tension on which may be adjusted to change the shape of the LVR or other catheter in which the pullwire is used.
The conveyor cable 18, shown in
Segmental tensioner 22, shown in
Method of Use
As an initial step, the RLC 10 is introduced using the well-known technique of transseptal catheterization from the right atrium (RA) into the left atrium (LA), such as by using a Brockenbrough needle assembly 12, 14 through the RLC 10, which is positioned in the right femoral vein (RFV) as shown in
The tracker balloon catheter is withdrawn from the RLC, and the conveyor cable 18 is inserted into the RLC 10 on the patient's right ride and advanced. This directs the tip of the cable 18 into the left femoral artery. A snare introduced into the left femoral artery grasps the ball tip 20 of the conveyor cable as shown in
Referring to
Once within the heart, the LVR is pushed strongly into the apex of the left ventricle by a pushing force applied to its proximal end.
The RLC is next withdrawn from the venous side while a pushing force is applied to the cable on that same side.
In
At this point, a significant pulling force is applied to the MVTD/tensioner assembly by the cable 18. This force is slightly more than the “push force” force on the MVTD 46 so as to pull the distal nose of the MVTD down and to the patient's left through the interatrial septum. Despite the pushing force of the LVR into the apex, with ever increasing pull force, there is a strong tendency to cause the loop of the cable contained in the steerable section of the LVR to be pulled upward into the valve structures above. This tendency is overcome by the synergistic downward pushing force exerted by the segmental tensioner as it enters the lumen at the distal end of the LVR in the LV apex (
In addition to the importance of maintaining the cable 18 loop in the apex of the ventricle, another key function of the LVR is to aid in the final steering of the MVTD into the center of the mitral valve ring at an angle that is perpendicular to the mitral valve ring plane. The user fine tunes the MVTD position within the ring through a combination of adjustments to pull wire tension, torqueing of the LVR, and push-pull of the LVR from the handle.
It can be appreciated that an automated alternative to the manual method and system described above is conceivable and within the scope of this disclosure. Such a system would include drive elements that engage and selectively push/pull the instruments at the venous side, and drive elements that engage and selectively push/pull the instrument at the arterial side. In such an embodiment, the MVTD and cable are attached to a drive unit (which may be table mounted) after connection of the MVTD and deployment of the LVR, just before the MVTD is set to enter the venous sheath. The drive unit may be one configured to allow the cable 18 to be set between rollers that will cause a pulling force to be applied to the cable at the arterial side while the delivery sheath of the MVTD is set among the rollers at the that will cause the MVTD to be pushed forward at the venous side at the same rate, causing the MVTD to move toward the mitral valve position. Such a system might employ a wired or wireless user controller. The controller can include a first input (e.g. a button, slider, etc) used to selectively cause movement (pulling or pushing force) at the arterial side and a second input used to selectively cause equal pulling and pushing forces at the venous side in a reverse direction. The controller preferably includes “dead man” switches, so that all motion stops instantly if either button is released. (The controller might also include a single input or mode of operation that causes the drive unit to simultaneously pull the cable and push the MVTD at the same rate.) A third input is used to cause an increased rate of movement in the pull direction to be greater than the rate of movement in the pull direction in order to steer the tip of the MVTD down and to the patient's left when traversing the interatrial septum and left atrium. A fourth input can be employed to cause more push than pulling force in order to drive the segmental tensioner harder into the protective sleeve of the steering section of the LVR in order to keep it pushed into the LV apex during increased tension on the cable during transit of the MVTD.
The disclosed system and method are described here as “guidewireless” because the step of moving the MVTD into position across the mitral valve site is performed without guidewires. Note that other steps may utilize guidewires without departing from the scope of the invention. As a non-limiting example, should the practitioner observe the tracker catheter heading off course as it approaches the aorta, a guidewire may be introduced via the arterial side into the distal lumen opening at the balloon catheter tip so that the tracker balloon catheter can track over the guidewire to the target vessel in the arterial vasculature
All patents and patent applications referred to herein, including for purposes of priority, are fully incorporated herein by reference.
This application is a continuation of U.S. application Ser. No. 16/396,677, filed Apr. 27, 2019, which is a continuation of PCT/US2017/62913, filed Nov. 22, 2017, which claims the benefit of the following U.S. Provisional Applications: U.S. 62/425,584, filed Nov. 22, 2016, U.S. 62/443,492, filed Jan. 6, 2017, U.S. 62/461,788, filed Feb. 21, 2017, and U.S. 62/473495, filed Mar. 20, 2017.
Number | Name | Date | Kind |
---|---|---|---|
5190050 | Nitzsche | Mar 1993 | A |
5873842 | Brennen et al. | Feb 1999 | A |
6004280 | Buck et al. | Dec 1999 | A |
6592581 | Bowe | Jul 2003 | B2 |
6613046 | Jenkins et al. | Sep 2003 | B1 |
7056314 | Florio et al. | Jun 2006 | B1 |
7115134 | Chambers | Oct 2006 | B2 |
7481805 | Magnusson | Jan 2009 | B2 |
7647124 | Williams | Jan 2010 | B2 |
7729782 | Williams et al. | Jun 2010 | B2 |
8096985 | Legaspi et al. | Jan 2012 | B2 |
8235916 | Whiting et al. | Aug 2012 | B2 |
8435227 | Takagi et al. | May 2013 | B2 |
8606369 | Williams et al. | Dec 2013 | B2 |
8827982 | Goode et al. | Sep 2014 | B2 |
8926588 | Berthiaume et al. | Jan 2015 | B2 |
8996135 | Elencwajg | Mar 2015 | B2 |
9072872 | Asleson et al. | Jul 2015 | B2 |
9078994 | Rosenman et al. | Jul 2015 | B2 |
9173646 | Fabro | Nov 2015 | B2 |
9220874 | Pillai et al. | Dec 2015 | B2 |
9320564 | Avitall et al. | Apr 2016 | B2 |
9511205 | Inoue | Dec 2016 | B2 |
9616197 | Serina et al. | Apr 2017 | B2 |
9814814 | Corbett et al. | Nov 2017 | B2 |
10105221 | Siegel | Oct 2018 | B2 |
20010005789 | Root et al. | Jun 2001 | A1 |
20040003819 | St. Goar et al. | Jan 2004 | A1 |
20040127847 | DuBois | Jul 2004 | A1 |
20060155158 | Aboul-Hosn | Jul 2006 | A1 |
20060167535 | Johnson | Jul 2006 | A1 |
20060217794 | Ruiz et al. | Sep 2006 | A1 |
20060217802 | Ruiz | Sep 2006 | A1 |
20070032850 | Ruiz et al. | Feb 2007 | A1 |
20070049906 | Magnusson | Mar 2007 | A1 |
20070060914 | Magnusson | Mar 2007 | A1 |
20070100299 | Magnusson | May 2007 | A1 |
20070112422 | Dehdashtian | May 2007 | A1 |
20070156233 | Kapadia et al. | Jul 2007 | A1 |
20070299403 | Crowe et al. | Dec 2007 | A1 |
20100160725 | Kiser et al. | Jun 2010 | A1 |
20100185172 | Fabro | Jul 2010 | A1 |
20100198056 | Fabro et al. | Aug 2010 | A1 |
20100198192 | Serina et al. | Aug 2010 | A1 |
20100198208 | Napp et al. | Aug 2010 | A1 |
20100249491 | Farnan et al. | Sep 2010 | A1 |
20110022057 | Eigler et al. | Jan 2011 | A1 |
20120041422 | Whiting et al. | Feb 2012 | A1 |
20120101442 | Legaspi et al. | Apr 2012 | A1 |
20120172656 | Walters et al. | Jul 2012 | A1 |
20140107399 | Spence | Apr 2014 | A1 |
20140276395 | Wilson et al. | Sep 2014 | A1 |
20140276782 | Paskar | Sep 2014 | A1 |
20140276904 | Hanson et al. | Sep 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140371719 | Carnevale | Dec 2014 | A1 |
20150258312 | Tuseth | Sep 2015 | A1 |
20150273136 | Osiev | Oct 2015 | A1 |
20150305864 | Quadri et al. | Oct 2015 | A1 |
20150328382 | Corbett et al. | Nov 2015 | A1 |
20160066993 | Avitall et al. | Mar 2016 | A1 |
20160074623 | Pillai et al. | Mar 2016 | A1 |
20160158506 | Eliasen et al. | Jun 2016 | A1 |
20160213472 | Kim | Jul 2016 | A1 |
20160220785 | Fabro | Aug 2016 | A1 |
20160317288 | Rogers et al. | Nov 2016 | A1 |
20160317289 | Tozzi | Nov 2016 | A1 |
20170224483 | Kizuka | Aug 2017 | A1 |
20170245988 | Siegel et al. | Aug 2017 | A1 |
20170258614 | Griffin | Sep 2017 | A1 |
20170361065 | Legaspi et al. | Dec 2017 | A1 |
20180043132 | Serina et al. | Feb 2018 | A1 |
20180078370 | Kovalsky et al. | Mar 2018 | A1 |
20180104398 | Corbett et al. | Apr 2018 | A1 |
20180311421 | Tuseth et al. | Nov 2018 | A1 |
20180318079 | Patel et al. | Nov 2018 | A1 |
20190117937 | Humphrey et al. | Apr 2019 | A1 |
20190151614 | Hsueh et al. | May 2019 | A1 |
Number | Date | Country |
---|---|---|
1534374 | Jan 2007 | EP |
1807143 | Jul 2007 | EP |
2687254 | Apr 2015 | EP |
2913080 | Sep 2015 | EP |
3142721 | Mar 2017 | EP |
3288491 | Mar 2018 | EP |
3302363 | Apr 2018 | EP |
200060995 | Oct 2000 | WO |
2005037345 | Apr 2005 | WO |
2006052651 | May 2006 | WO |
2007149974 | Dec 2007 | WO |
2008012914 | Jan 2008 | WO |
2009137712 | Nov 2009 | WO |
2010085456 | Jul 2010 | WO |
2010085457 | Jul 2010 | WO |
2012178115 | Dec 2012 | WO |
2013181397 | Dec 2013 | WO |
2014065714 | May 2014 | WO |
2014138482 | Sep 2014 | WO |
2014197962 | Dec 2014 | WO |
2015175718 | Nov 2015 | WO |
2016176409 | Nov 2016 | WO |
2016196933 | Dec 2016 | WO |
2017139246 | Aug 2017 | WO |
2017155892 | Sep 2017 | WO |
1994003227 | Apr 2018 | WO |
2019055154 | Mar 2019 | WO |
Entry |
---|
Sondergaard, Lars et al., First-in-Human Case of Transfemoral CardiAQ Mitral Valve Implantation, Circ. Cardiovasc Interv. 2015, 10 pages. |
International Search Report and Written Opinion for corresponding PCT/US2017/062913 dated Feb. 8, 2018, 7 pages. |
International Search Report and Written Opinion for PCT/US2020/017370 dated Nov. 6, 2020, 11 pages. |
Supplemental European Examination Report for European Patent Applicaction No. 17874335.7, corresponding to PCT/US2017/062913, dated Jul. 9, 2020, 21 pages. |
Translation of Office Action for Japanese Patent Application 2019-547598, corresponding to PCT/US2017/062913, dated Oct. 29, 2021, 4 pages. |
Number | Date | Country | |
---|---|---|---|
20210177389 A1 | Jun 2021 | US |
Number | Date | Country | |
---|---|---|---|
62473495 | Mar 2017 | US | |
62461788 | Feb 2017 | US | |
62443492 | Jan 2017 | US | |
62425584 | Nov 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16396677 | Apr 2019 | US |
Child | 17188936 | US | |
Parent | PCT/US2017/062913 | Nov 2017 | US |
Child | 16396677 | US |